aripiprazole has been researched along with Anochlesia in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y | 1 |
| Agai-Csongor, E; Bielik, A; Domány, G; Galambos, J; Gémesi, L; Greiner, I; Gyertyán, I; Ignácz-Szendrei, G; Keseru, GM; Kiss, B; Laszlovszky, I; Laszy, J; Magdó, I; Nógrádi, K; Sághy, K; Schmidt, E; Vágó, I; Zájer-Balázs, M | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Akber Aisa, H; Chen, W; Guo, S; He, Y; Hu, T; Jiang, X; Li, J; Liu, Y; Shen, J; Wang, Y; Wang, Z; Wu, C; Xiamuxi, H; Xie, Y; Xu, M; Yang, F; Zhang, J; Zhao, Q | 1 |
| Abe, M; Egashira, N; Fujiwara, M; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R | 1 |
| Amano, T; Asato, M; Hashimoto, K; Ikegami, D; Kuzumaki, N; Matsushima, Y; Nakamura, A; Narita, M; Niikura, K; Shiokawa, M; Suzuki, T; Takagi, S; Takei, D; Tsurukawa, Y | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| Avenet, P; Bergis, O; Boulay, D; Griebel, G | 1 |
| Calas, AG; Goursaud, S; Hermans, E; Jeanjean, AP; Koener, B; Maloteaux, JM; Van De Stadt, M | 1 |
| Altar, CA; Burris, KD; Dunn, B; Hirose, T; Imaoka, T; Kikuchi, T; Miwa, T; Molinoff, PB; Nakai, M; Nakai, S; Okazaki, H; Tottori, K; Uwahodo, Y; Yamada, S | 1 |
| Altar, CA; Burris, KD; Hirose, T; Kikuchi, T; Kitagawa, H; Miwa, T; Nabeshima, T; Uwahodo, Y; Yamada, S | 1 |
| Fletcher, PJ; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
| Clarke, K; Davies, CH; Forbes, IT; Gribble, A; Hill, M; Jones, DN; Newson, M; Reavill, C; Rourke, C; Scott, C; Westaway, J; Wood, MD | 1 |
| Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
| Guimarães, FS; Leite, JV; Moreira, FA | 1 |
| Freichel, C; Künnecke, B; Maco, M; Moreau, JL; Nordquist, RE; Riemer, C; Risterucci, C; Spooren, W; von Kienlin, M | 1 |
| Hirose, T; Kikuchi, T; Miwa, T; Morita, S; Oshiro, Y; Tottori, K; Uwahodo, Y | 1 |
17 other study(ies) available for aripiprazole and Anochlesia
| Article | Year |
|---|---|
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine Antagonists; GABA Modulators; Male; Mice; Mice, Inbred ICR; Molecular Structure; Piperazines; Quinolones; Rats; Stereotyped Behavior; Structure-Activity Relationship | 1998 |
Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Binding, Competitive; Biological Availability; Brain; Catalepsy; Cognition; Humans; Indicators and Reagents; Male; Maze Learning; Memory Disorders; Quantitative Structure-Activity Relationship; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereotyped Behavior; Sulfonamides | 2007 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dogs; Half-Life; Humans; Inhibitory Concentration 50; Mice; Microsomes, Liver; Pyrimidinones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Structure-Activity Relationship | 2017 |
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Catalepsy; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Indoles; Ketanserin; Male; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Piperidines; Postural Balance; Psychomotor Performance; Pyridines; Quinolones; Quinpirole; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists | 2008 |
Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Hyperkinesis; Male; Mice; Mice, Inbred ICR; Morphine; Nucleus Accumbens; Piperazines; Prochlorperazine; Quinolones; Reward; Severity of Illness Index | 2008 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Dopamine Plasma Membrane Transport Proteins; Glycine Plasma Membrane Transport Proteins; Hyperkinesis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Piperazines; Quinolones; Receptors, N-Methyl-D-Aspartate | 2010 |
Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
Topics: Animals; Apomorphine; Aripiprazole; Buffers; Catalepsy; Cell Membrane; Cerebral Cortex; Corpus Striatum; Domperidone; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Antagonism; Drug Partial Agonism; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Hippocampus; Male; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Stereotyped Behavior; Up-Regulation | 2011 |
Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Corpus Striatum; Dopamine; Haloperidol; Limbic System; Male; Mice; Mice, Inbred ICR; Piperazines; Quinolones; Risperidone; Time Factors | 2003 |
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blepharoptosis; Catalepsy; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Head Movements; Male; Methoxydimethyltryptamines; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Prosencephalon; Quinolones; Rats; Rats, Wistar; Risperidone; Serotonin; Stereotyped Behavior | 2004 |
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Catalepsy; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Immunohistochemistry; Male; Motor Activity; Oncogene Proteins v-fos; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Risperidone | 2006 |
Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Binding, Competitive; Biotransformation; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Guanosine 5'-O-(3-Thiotriphosphate); HeLa Cells; Humans; Male; Motor Activity; Oxidopamine; Piperazines; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Species Specificity; Transfection | 2006 |
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; Catalepsy; Clozapine; Dopamine Agonists; Drug Evaluation, Preclinical; Haloperidol; Male; Piperazines; Prolactin; Proto-Oncogene Proteins c-fos; Psychotic Disorders; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Serotonin Antagonists; Treatment Outcome | 2007 |
Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Central Nervous System Stimulants; Cocaine; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Partial Agonism; Excitatory Amino Acid Antagonists; Glutamine; Haloperidol; Hyperkinesis; Ketamine; Locomotion; Male; Mice; Motor Activity; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Time Factors | 2008 |
Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
Topics: Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Data Interpretation, Statistical; Dopamine Agonists; Hallucinogens; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Motor Activity; N-Methylaspartate; Piperazines; Postural Balance; Psychoses, Substance-Induced; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Serotonin Receptor Agonists | 2008 |
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Catalepsy; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Male; Mice; Mice, Inbred ICR; Motor Activity; Oxidopamine; Piperazines; Presynaptic Terminals; Quinolones; Radioligand Assay; Rats; Reserpine; Spiperone; Stereotyped Behavior; Synapses; Tritium | 1995 |